Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MF59-adjuvanted Influenza Vaccine in Korean Elderly
NCT01222403Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of influenza vaccine (surface antigen, inactivated, adjuvanted) in influenza, sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
influenza vaccine (surface antigen, inactivated, adjuvanted)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01222403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222403.